MedTrace Logo

Xerecept Intravenous Dose Escalation in Japanese and Caucasian Volunteers

NCT00820092 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2013-07-30

No results posted yet for this study

Summary

1. To investigate the safety and tolerability of Xerecept during and following a 24-hour intravenous administration to healthy Japanese to healthy Japanese and Caucasian subjects
2. To compare the PK profile of hCRF during and following a 24-hour intravenous Xerecept administration between healthy Japanese and Caucasian subjects

Conditions

Interventions

DRUG

Xerecept 1.0

24 hour infusion

DRUG

Xerecept 2.0

24 hour infusion

DRUG

Xerecept 3.0

24 hour infusion

Sponsors & Collaborators

  • Celtic Pharma Development Services

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-03-31
Completion
2009-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00820092 on ClinicalTrials.gov